Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
SPIL1033 is subcutaneous injection is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus.
In this study, efficacy and safety of SPIL1033 will be evaluated. Subjects will receive SPIL1033 or placebo, 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, India
- SPIL Site 22
-
Hyderabad, Andhra Pradesh, India
- SPIL Site 25
-
Hyderabad, Andhra Pradesh, India
- SPIL Site 26
-
Visakhapatnam, Andhra Pradesh, India
- SPIL Site 23
-
-
Gujrat
-
Ahmedabad, Gujrat, India
- SPIL Site 1
-
Ahmedabad, Gujrat, India
- SPIL Site 2
-
Ahmedabad, Gujrat, India
- SPIL Site 3
-
Rajkot, Gujrat, India
- SPIL Site 5
-
Surat, Gujrat, India
- SPIL Site 6
-
Surat, Gujrat, India
- SPIL Site 7
-
Surat, Gujrat, India
- SPIL Site 8
-
Surat, Gujrat, India
- SPIL Site 9
-
Vadodara, Gujrat, India
- SPIL Site 10
-
-
Karnataka
-
Bangalore, Karnataka, India
- SPIL Site 30
-
Bangalore, Karnataka, India
- SPIL Site 31
-
Bangalore, Karnataka, India
- SPIL Site 33
-
Manipal, Karnataka, India
- SPIL Site 29
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, India
- SPIL Site 35
-
-
Maharashtra
-
Nagpur, Maharashtra, India
- SPIL Site 21
-
Nagpur, Maharashtra, India
- SPIL Site 24
-
Nashik, Maharashtra, India
- SPIL Site 32
-
Pune, Maharashtra, India
- SPIL Site 11
-
Pune, Maharashtra, India
- SPIL Site 12
-
-
Orrissa
-
Bhubaneshwar, Orrissa, India
- SPIL Site 13
-
-
Rajasthan
-
Jaipur, Rajasthan, India
- SPIL Site 14
-
Jaipur, Rajasthan, India
- SPIL Site 15
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, India
- SPIL Site 34
-
-
Tamilnadu
-
Chennai, Tamilnadu, India
- SPIL Site 16
-
Coimbatore, Tamilnadu, India
- SPIL Site 17
-
Coimbatore, Tamilnadu, India
- SPIL Site 20
-
Madurai, Tamilnadu, India, 625020
- SPIL Site 18
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India
- SPIL Site 27
-
Lucknow, Uttar Pradesh, India
- SPIL Site 28
-
-
kARNATAKA
-
Bangalore, kARNATAKA, India
- SPIL Site 19
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects 20 years of age and older.
- Established clinical diagnosis of type 2 diabetes mellitus treated with diet and exercise or anti-diabetic agents as monotherapy or combination therapy.
- Weight stable: their weight should not have varied more than 10% of screening visit weight, within 6 months prior to screening visit.
- Women of child bearing potential practicing an acceptable method of birth control as judged by the investigator(s); with a negative urine pregnancy test.
- Willing to participate and give written informed consent.
Exclusion Criteria:
- Previous exposure to exenatide (anti-exenatide antibodies at screening) or a glucagon-like peptide (GLP-1) analogue.
- Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, rimonabant, or similar over-the-counter medications) within 3 months of screening.
- Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of trial entry.
- Severe renal impairment (creatinine clearance <30 ml/min) or end stage renal disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks.
To be self-administered twice daily.
|
|
Experimental: SPIL1033
|
5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks.
To be self-administered twice daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline to End of Study in Hemoglobin A1c (HbA1c)
Time Frame: 24 weeks
|
24 weeks
|
|
Change From Baseline to End of Study in Fasting Plasma Glucose (FPG)
Time Frame: 24 weeks
|
24 weeks
|
|
Count and Percentage of Subjects Positive for Anti-exenatide Antibodies
Time Frame: 24 weeks
|
24 weeks
|
|
Count and Percentage of Subjects With Potentially Immune-related Treatment-emergent Adverse Events (TEAEs)
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in 2hour Postprandial Glucose (2-h PPG)
Time Frame: 24 weeks
|
24 weeks
|
|
Change From Baseline in Triglycerides
Time Frame: 24 weeks
|
24 weeks
|
|
Change From Baseline in Low Density Lipoproteins
Time Frame: 24 weeks
|
24 weeks
|
|
Change From Baseline in High Density Lipoproteins
Time Frame: 24 weeks
|
24 weeks
|
|
Change in Body Weight
Time Frame: 24 weeks
|
24 weeks
|
|
Subjects Achieving Hemoglobin A1c (HbA1c) < 7%
Time Frame: 24 weeks
|
24 weeks
|
|
Change From Baseline in Very Low Density Lipoproteins
Time Frame: 24 weeks
|
24 weeks
|
|
Change From Baseline in Total Cholesterol
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CLR_10_33
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.